SEATTLE, WA--(Marketwired - Oct 14, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS), today announced it
would be a featured presenter at the SeeThru Equity Fall Microcap Investor Conference being held on October 17, 2016 at the
Convene, 730 Third Avenue, New York, NY. The Company will also be a featured presenter at the Dawson James Small Cap Growth
Conference being held October 20, 2016 at the Wyndham Grand Jupiter at Harbourside Place, Jupiter FL.
Kyle Guse, CFO and General Counsel will discuss the Company's business model and growth strategies at the SeeThru Equity
Conference on Monday, October 17, 2016 at 11:30 am Eastern time. Mr. Guse will present at the Dawson James Conference on
Thursday, October 20, 2016 at 1:45 pm Eastern time. Mr. Guse will be available for one-on-one investor meetings at both
events.
For more information on the SeeThru Equity Fall Microcap Investor Conference please visit: http://www.seethruequity.com/
For more information on the Dawson James Small Cap Growth Conference please visit: http://dawsonjames.com/conference/2015-conferences/
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the
risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by
Atossa, lower than anticipated rate of patient enrollment, results of clinical studies and timing of publication of those
results, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by others including with respect to Fulvestrant, such as patent
rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.